Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lineage Cell Therapeutics, Inc.
Study AST-OPC1-02 is a Phase 1/2a open-label, multi-center long term follow-up (LTFU) study for twenty-five (25) subjects with cervical SCI that were administered AST-OPC1 cells in the main dose-escalation study AST-OPC1-01. The purpose of this study is to monitor long-term safety in subjects for 15 years post AST-OPC1 administration.
Age
18–69
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who received AST-OPC1 under Study AST-OPC1-01
Reconfirmation of consent for long-term follow-up
You may not be if
Subjects who, for geographic or compliance reasons, are inappropriate candidates for participation in a long-term follow-up study in the opinion of the Investigator
Clareo Health | LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1
